Creating the
medications of

Teva’s innovative specialty pharmaceuticals

Teva’s unmatched scientific and commercial expertise has propelled us to a leading position in specialty pharmaceuticals. Teva develops and manufactures specialty medicines and new therapeutic entities (NTEs) that meet patient needs, most significantly in central nervous system (CNS), pain and respiratory conditions, with additional focus on the key areas of women’s health, oncology and biologics.

Teva Canada Innovation

Teva’s brand-name division, Teva Canada Innovation, develops and markets leading proprietary medications in the areas of multiple sclerosis, Parkinson’s disease and acute migraine attacks.

Our research activities

Teva Canada Innovation also concentrates investments and research activities on Phase II and III clinical trials focused on several other neurological and neurodegenerative diseases. Our clinical research unit was formally established in 2003.

For more information on Teva Canada Innovation, please visit